---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-24-000078"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:21:22.382753+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evolus Q1 revenue up 42% YoY to $59.3M; on track for non-GAAP profitability in Q4 2024

## Summary
- Net revenue $59.3M (+42% YoY); gross margin 68.3%; non-GAAP loss from ops $0.9M, narrowing from Q4 2023's $3.7M.
- Reaffirms FY2024 revenue guidance of $255-265M; expects non-GAAP profitability in Q4 2024 and full-year 2025.
- FDA submission for Evolysse dermal fillers within 90 days; expanding into Australia and Spain with Nuceiva.
- Added 700+ new customer accounts; reorder rate ~70%; Evolus Rewards members ~825,000.

## SEC filing metadata
- accession: 0001570562-24-000078
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056224000078/0001570562-24-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056224000078/eols-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-24-000078
- JSON: https://secwatch.observer/filing/0001570562-24-000078.json
- Plain text: https://secwatch.observer/filing/0001570562-24-000078.txt

## Key facts
- Earnings Releases
  Evolus, Inc. reported the first quarter ended March 31, 2024 results: revenue $59.3 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $59.3 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total net revenues for the first quarter of 2024 increased 42% to $59.3 million from $41.7 million in the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1570562/000157056224000078/0001570562-24-000078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.